Alentis raises €163.3M Series D round
12 November 2024· Allschwil, Switzerland· health, oncology, biotech, b2b, deep_hardware
The funding will be used to advance the clinical development of Alentis' lead anti-Claudin-1 antibody-drug conjugates (ADCs), ALE.P02 and ALE.P03, into Phase 1/2 clinical trials for solid tumors.
Investors
LeadOrbiMed
Also participating
BpifranceRA Capital ManagementNovo HoldingsJeito CapitalCatalio Capital ManagementFrazier Life SciencesLongitude CapitalPiper Heartland Healthcare CapitalAvego Bioscience CapitalMorningside Venture InvestmentsBB Pureos Bioventures
About Alentis
Stage
Series D
Headquarters
Allschwil, Switzerland
Founded
2019
Team Size
51–200
Sectors
healthoncologybiotechb2bdeep_hardware